London, UK (PRWEB) April 23, 2014
To date, more than 32 million people worldwide are living with cancer. The most frequently occurred types of cancer include breast, lung, colorectal and prostate cancer; these four types account for around 40% of all cancer cases. In 2012 alone, nearly 8.2 million people globally died from cancer, with approximately 60% of the deaths occurring across the less developed regions. At present, cancer ranks the 2nd most common cause of death in the USA; around 13.7 million Americans have had cancer in the past several years or are suffering from the disease at the present time. In 2013, nearly 580,000 Americans died from cancer, and it is estimated that 174,100 of these deaths could have been prevented. 33% of cancers diagnosed in the US are attributed to certain lifestyle factors. Presently, breast cancer calls for almost 11% of the total number of cancers diagnosed worldwide; more than 1.7 million women worldwide are diagnosed to have breast cancer annually. As of 2012, around 522,000 women died of breast cancer.
On the whole, the world cancer biomarker and associated companion diagnostic market have a number of nice growth opportunities. This industry will likely revolutionize the overall healthcare system and improve therapeutic effectiveness and also reduce the severity of adverse effects. The cancer biomarkers industry has an enormous potential for investment, and it is predicted to see the emergence of novel genetic-based in vitro diagnostics in the upcoming years.
New research report “Global & USA Cancer Biomarker Market to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends, and Pipeline Analysis)” worked out by Kelly Scientific Publications is now available at MarketPublishers.com.
Title: Global & USA Cancer Biomarker Market to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends, and Pipeline Analysis)
Published: May, 2014
Price: US$ 3,400.00
The cutting-edge report provides a comprehensive analysis of the world cancer biomarker industry and examines the impact of the industry’s development on the overall healthcare system. It touches upon the increasing market interest in personalized medicine, oncogenic biomarkers, associated market environment and companion diagnostics, and many other important industry related aspects. The study presents a detailed description of the current world cancer biomarkers market scenario, investigates the key factors driving the market growth, reviews the existing technologies and diagnostic tests, traces the latest industry developments, characterizes the major industry development trends, and also discloses a complete set of top-level data and figures showing historical and actual industry performance. Besides, the report provides exhaustive forecasts of the cancer biomarkers industry performance up to 2018.
More new research reports by the publisher can be found at Kelly Scientific Publications page.